For more than twenty years, the Lewy field has diagnosed by proxy. Amyloid got its scan in 2004, tau got its scan a decade later, and clinicians facing a person with fluctuating attention, visual hallucinations and dream enactment have had to triangulate: a dopamine transporter scan that shows the loss of cells rather than the protein that killed them, a sleep study, a careful history. The protein itself, misfolded alpha-synuclein, stayed invisible. On 27 May 2026, Science Translational Medicine published the paper the field has been waiting on: Saw and colleagues, working across MODAG GmbH, University Hospital Tuebingen and the Max Planck Institute for Multidisciplinary Sciences, reported the development, preclinical validation and first-in-human evaluation of a carbon-11 tracer called [11C]MODAG-005. The human part is small and should be read as such: imaging in patients with clinically established MSA of the cerebellar type, MSA of the cerebellar and parkinsonian type, and Parkinson's disease, three patients in all, with the tracer accumulating in regions where synuclein pathology is expected.

The chemistry is the interesting part, because it explains both the success and the doubt. MODAG-005 was built out of anle138b (emrusolmin), the company's aggregate-modulating drug candidate, which means the tracer and the therapy are aiming at the same physical feature of a fibril. A structural preprint posted to bioRxiv in April 2025 by the Goettingen NMR group, using cryo-electron microscopy, NMR and molecular dynamics on lipidic synuclein fibrils, located two binding sites for MODAG-005: one on the fibril surface, one inside a tubular cavity running through the fibril, with occupancy depending on how the fibrils were prepared. That same preprint cites affinity of about 0.2 nanomolar in MSA brain tissue with roughly 195-fold selectivity over tau and 3,600-fold over amyloid-beta aggregates. The authors' own preprint of the tracer work describes saturation binding in MSA tissue resolving into two sites, a high-affinity one at 0.25 nanomolar and a low-affinity one at 31.9 nanomolar. A tracer that binds inside a cavity is a tracer whose performance depends on the exact fold of the fibril it meets, and the folds differ between diseases.

That is the crux. In MSA, aggregated synuclein sits in glial cytoplasmic inclusions inside oligodendrocytes, densely and abundantly, in white matter tracts that make an obliging PET target. In Parkinson's disease and dementia with Lewy bodies, the deposits are neuronal, sparser, differently packed, and scattered through cortex where other pathologies also live. The field has hit this wall before. In a 2017 Movement Disorders study of Mayo Clinic brain bank tissue, Koga and colleagues found the tau ligand PBB3 at 10 nanomolar produced no significant autoradiographic binding in Lewy body disease cases, while binding striatopallidal fibres in MSA cases with high inclusion density. In 2023, Nature Communications reported [18F]ACI-12589 in 8 controls, 23 people with synucleinopathies (13 MSA, 8 Parkinson's, 2 DLB) and 11 with other neurodegenerative diseases: clear retention in MSA cerebellar white matter, and nothing comparable in the Lewy cases. There is a caution buried in the MODAG preprint too. Frontal cortex autoradiography showed raised binding not only in Parkinson's tissue but in Alzheimer's and progressive supranuclear palsy tissue as well, which matters in DLB, where Alzheimer's co-pathology is common rather than rare.

Since publication, the story has moved fast and mostly outside peer review. MODAG has re-engineered the molecule for fluorine-18, which has a two-hour half-life and can be shipped, unlike carbon-11, which needs a cyclotron in the building. At AD/PD in London in March 2026, Armin Giese showed images from two people with Parkinson's, one with MSA, two with DLB and one healthy control, according to Alzforum's conference reporting, with the DLB scans showing signal in basal ganglia, midbrain, cortex and a hot spot in the amygdala, a region where DLB pathology is often heavy. Lawrence Honig of Columbia, quoted in the same coverage, noted that "very few cases were shown" while calling the anatomical patterns encouraging. Two MODAG trial registrations appeared on ClinicalTrials.gov in June: a whole-body dosimetry study of [18F]MODAG-009 in about six healthy volunteers, first posted 1 June 2026 and listed as started on 27 May, and a 13-participant early-phase study of the same tracer in synucleinopathies, first posted 10 June and started 13 May. The conditions listed for that second study are multiple system atrophy, Parkinson's disease and healthy adults. Dementia with Lewy bodies is not on the list.

For a family living with a Lewy body diagnosis, the practical distance between this paper and a clinic appointment is still long. There is no approved synuclein PET scan anywhere, the carbon-11 version cannot travel, and the total peer-reviewed human experience with MODAG-005 is three patients with no published control comparison. What the tracer may deliver first is not diagnosis but evidence: an objective way to ask whether a drug aimed at synuclein aggregates is actually reaching them, which is precisely what the Science Translational Medicine paper demonstrated for anle138b in mouse and MSA brain tissue and in fibril-injected rats. If that holds in people, trials get faster and cleaner, and the treatments that eventually reach families get tested against the protein rather than against a questionnaire.